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Abstract 
Nowadays, wound healing delay due to diabetes is considered to be closely related to the accumulation of advanced 
glycation end products (AGEs). Although mesenchymal stem cells (MSCs) exhibit positive effects on diabetic wound 
healing, related mechanisms are still not fully elucidated. It has been reported that MSCs can improve the activity of 
autophagy in injured tissues, thereby playing an important role in wound healing. The autophagy induced by MSCs 
may be beneficial to diabetic wound healing via removing AGEs, which provide new ideas for clinical treatment of 
diabetic wounds with the potential of broad application prospects. In this study, the current research situation and 
application prospect of umbilical cord-derived MSCs on the clearance of AGEs in diabetic wound were reviewed.
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Background
Currently, the incidence of diabetes is increasing year by 
year. A high morbidity of diabetic foot ulcers (more than 
25%) is always found in diabetic patients [1]. As a com-
mon complication of diabetes, chronic diabetic wounds 
with the characteristics of low cure rate and high ampu-
tation rate not only causes great pain to patients, but also 
increases the burden of the family and society. Despite 
the existing therapy methods, there are still no effective 
therapy measures available for the treatment of diabetic 
wounds owing to its complex mechanisms and character-
istics. Therefore, it is urgent to search for new approaches 
to promote wound healing in diabetic patients.
The mechanisms of diabetic wound healing are com-
plicated. It has been shown that the mechanisms of dia-
betic wound healing are associated with various factors, 
including ischemia and hypoxia, abnormal inflammatory 
response, excessive microbial load, peripheral neuropa-
thy, and abnormal expressions of matrix metalloprotein-
ases and vascular endothelial growth factors. However, 
clear mechanisms of diabetic wound healing have not 
been fully clarified. With the deepening study on patho-
genesis of diabetic skin lesions, advanced glycation end 
products (AGEs) have been revealed to be closely related 
to the delayed healing of diabetic skin wounds [2]. AGEs 
are the final products of non-enzymatic catalytic reac-
tion of amino (proteins, lipids, and nucleic acids) and 
aldehyde groups of carbohydrate under continuous 
high level of glucose conditions. In patients with diabe-
tes, pathologic high blood glucose could always accel-
erate the glycosylation reaction, thereby producing a 
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AGEs cannot be recovered to normal level by reducing 
blood glucose. AGEs, as the direct products of diabetic 
metabolic remodeling, are an important environmen-
tal medium for changes of skin tissue cells, extracellular 
matrix, and cytokines. Therefore, accumulation of AGEs 
could induce the occurrence of damaged skin in diabetic 
patients. Besides, AGEs also exhibit the ability to inhibit 
fibroblast differentiation, proliferation, and migration, 
which could delay the process of wound healing through 
decreasing the expression of collagen [3]. Some animal 
experiments have suggested that the application of anti-
AGE agents could promote the healing of soft tissue 
wounds [4]. Although the accumulation of dermal AGEs 
has been considered as a fundamental cause of diabetic 
wound formation or refractory healing, only few effec-
tive methods have been revealed to be able to inhibit and 
remove AGEs in the wound so far [5, 6].
Research status
Recently, some positive effects of cathepsins on clear-
ance of AGEs were revealed in vivo. Reported as follows, 
Grimm et  al. [7] have demonstrated that cathepsin D 
plays an important role in the degradation of intracel-
lular AGEs. Meanwhile, a further investigation of them 
has also shown that both cathepsin D and L have signifi-
cant positive roles in the reducing of toxicity caused by 
AGEs [8]. Moreover, phytopharmaceutical Dispo85E is 
also reported having the ability to remove AGEs through 
the autophagy-lysosomal pathway induced by hepatocyte 
growth factor both in vivo and in vitro [9]. As an impor-
tant protective mechanism in eukaryotic cells, autophagy 
plays a crucial role in the maintaining of homeostasis 
in the intracellular environment. During this process, 
autophagosome is firstly formed by packaging the cyto-
plasmic proteins and organelles into a double mem-
brane, and then combined to the lysosome to form an 
autolysosome. Based on this autolysosome, the expres-
sions of cathepsins will be obviously induced in lyso-
some, while the activity of lysosome is activated. Since 
autophagy is able to degrade toxic protein aggregation, 
damaged mitochondria, and other cellular organelles in 
cells [10], the accumulation of AGEs, a production of 
glucose metabolism, may also be removed by autophagy/
cathepsin pathway. Nowadays, several small-molecule 
activators involved in autophagy pathways such as rapa-
mycin, trehalose, lithium, and rilmenidine have been 
identified to be able to up-regulate autophagy activity 
and promote the degradation of the polyproteins. How-
ever, the application of these factors is still limited in the 
clinical setting. For example, the common autophagy 
inducer rapamycin is a major regulatory protein in insu-
lin signaling pathway, which could also influence many 
other metabolic pathways. Meanwhile, the autophagy 
induction process of rapamycin is relatively slow with a 
long indirect acting time, and the effects of rapamycin 
were always temporary [11]. Therefore, searching for new 
ideal autophagy inducer exhibited important application 
values in the clinical setting.
Until now, there are still some patients with diabetic 
wound failed to cure in spite of continuous development 
on the treatment technology of diabetic wounds [12]. 
Recently, the advent of stem cell therapy, which is con-
sidered to be the basis of tissue regeneration, has brought 
great hope to these diabetic patients [13]. Mesenchymal 
stem cells (MSCs) are a kind of tissue stem cells with mul-
tiple differentiation potential, which are initially found in 
bone marrow. The promotion effect of different sources 
of MSCs on diabetic wound healing has been investigated 
by several researchers. Local application of allogeneic 
bone marrow-derived MSCs could promote wound heal-
ing in diabetic rats [14]. Meanwhile, adipose tissue and 
hair follicle dermal sheath-derived MSCs are also benefi-
cial to chronic wound healing in patients with diabetes 
[15, 16]. Moreover, compared with bone marrow-derived 
MSCs, umbilical cord-derived MSCs (UCMSCs) possess 
better biological characteristics such as easy obtainabil-
ity, rich source, no ethical problems, and strong prolif-
eration potential and show effective promotion effect on 
wound healing of skin ulcer in patients suffered with type 
2 diabetes [17]. Further research has indicated that posi-
tive effects of UCMSCs on wound healing were associ-
ated with differentiation into keratinocyte and release of 
ICAM-1, TIMP-1, and VEGF-A [18]. Although the accu-
mulation of AGEs has been identified to be one of the 
fundamental causes of impaired wound healing in diabe-
tes [5], the scavenging effects of UCMSCs on AGEs and 
its related molecular mechanism are still elucidated.
Preliminary results on the relations between autophagy 
and wound healing have been shown by various studies. 
As reported, the expression of autophagy-related gene 
Beclin-l in burn wound was significantly increased, and 
increased autophagy was found to be helpful to wound 
healing [19]. However, excessive autophagy could induce 
apoptosis and result in delay in wound healing [20]. In 
addition, similar to apoptosis and necrosis, autophagy 
also serves a vital role in the process of deepening wound 
[21, 22]. It has been reported that adenosine could pro-
mote wound healing of diabetic ischemic ulcers through 
improving autophagy of endothelial progenitor cells 
[23]. MSC transplantation was beneficial to carbon tet-
rachloride-induced liver regeneration and survival of 
pulmonary epithelial cells in acute lung injury through 
autophagy upregulation [24, 25]. MSCs are also consid-
ered to be able to alleviate beta cell damage induced by 
chronic high glucose via regulation of autophagy both 
in  vivo and vitro [26]. All the above researches have 
Page 3 of 4Han et al. Eur J Med Res  (2017) 22:11 
illustrated that enhanced autophagy activity is favora-
ble in the regeneration and reparation of injured tissue 
cells. On the other hand, MSCs are also reported being 
able to activate autophagy, thereby removing intracel-
lular accumulation of toxic proteins and increasing the 
viability and survival of neurons [27]. Meanwhile, MSC-
induced autophagy could also remove abnormal proteins 
or amino acids in  vivo and promote cell repair. How-
ever, the mechanisms and promotion effects of MSCs on 
autophagy activity and scavenging capacity in diabetic 
wounds are still unclear. Hence, research on the clear-
ance effects of autophagy induced by MSC transplanta-
tion in wounds and its related molecular mechanism will 
become a hot topic and urgently need to be concerned.
Diabetic wounds are not only accompanied by the 
accumulation of high glucose and AGEs, but also asso-
ciated with ischemia and hypoxia. Under anoxic condi-
tion, the dissociation of Beclin-1 from Bcl-XL and Bcl-2 
could be induced by activated hypoxia-inducing factor 
1α (HIF-1α) through upregulated BNIP3, and then the 
released Beclin-l could promote autophagy via serving 
as a positive regulator in this procedure. HIF-1α/BNIP3/
Beclin-1 has been considered to be an important sign-
aling pathway in the upregulation of autophagy under 
hypoxia [28]. The expression of HIF-1α is significantly 
reduced in diabetic skin wounds [29], while MSCs have 
been found to promote wound healing through upregu-
lating HIF-1α in fibroblast cells [30]. Therefore, we sus-
pected that the wound healing might be improved by 
MSC transplantation-induced autophagy via the HIF-1α/
BNIP3/Beclin-1 pathway and the clearance of AGEs 
through autophagy/cathepsin.
Application prospect
To sum up, autophagy/cathepsin is able to enhance cell 
viability and proliferation ability through clearance of 
intracellular AGEs. As a new approach to promote wound 
healing, UCMSC application has certain safety and no 
side effects, as well as a good ability in clearing AGEs via 
enhancing autophagy; therefore, UCMSCs may become 
an ideal autophagy inducer in the promotion of wound 
healing and provide new ideas and strategies for the 
treatment of diabetic wound healing in the clinical set-
ting. However, the popularization and application of fur-
ther clinical research findings are still required to further 
confirm the effects of this method in increasing wound 
healing rate, reducing amputation rate, hospital stay and 
costs, relieving the pain and improving the life quality of 
diabetic patients with chronic wounds, as well as reduc-
ing the burden of family and society. At present, with a 
high prevalence of diabetes, the rate of diabetic patients 
complicated with chronic ulcer wound is grown to 25%. 
The clinical application of UCMSCs in the treatment of 
diabetic wounds will bring out the significant economic 
and social benefits with a broad prospective.
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